Hypertensive Emergency Pharmacotherapy
Core concept: Hypertensive emergency is severe blood-pressure elevation with acute target-organ injury. Treatment uses titratable therapy to stop ongoing injury without causing ischemia from an excessive or overly rapid pressure drop.
Key clinical distinction: A very high BP without acute organ injury is not the same problem. Hypertensive emergency requires IV therapy and organ-specific targets; severe asymptomatic hypertension usually does not require emergency IV lowering.
Prescribing priority: Identify the injured organ first, then choose a rapidly titratable IV agent and BP target that fit the syndrome – especially aortic dissection, acute pulmonary edema/ACS, stroke, pregnancy, and catecholamine excess.
The Emergency Is the Target-Organ Injury
Hypertensive emergency can occur with encephalopathy, intracerebral hemorrhage, acute ischemic stroke requiring reperfusion, acute coronary syndrome, acute LV failure with pulmonary edema, aortic dissection, rapidly progressive kidney injury, eclampsia, or other acute target-organ damage. The absolute BP is important, but the presence and type of organ injury determine the urgency and target (Williams et al., 2026).
Severe asymptomatic hypertension can often be managed by restarting or intensifying oral therapy and correcting contributors such as pain, anxiety, withdrawal, or medication nonadherence. Rapid IV treatment without acute organ injury can cause harm (Williams et al., 2026).
General BP-Lowering Strategy
For most hypertensive emergencies without a condition-specific exception, reduce systolic blood pressure by no more than approximately 25% during the first hour, then, if stable, lower BP toward <160/100 mm Hg over the next 2–6 hours, with gradual further lowering over the following 24–48 hours. The aim is to avoid excessive early reduction, not to achieve exactly 25%. Aortic dissection, severe preeclampsia/eclampsia, catecholamine-mediated crisis, and acute stroke require syndrome-specific targets and pacing (Williams et al., 2026).
Common IV Agents
Agent choice is syndrome specific. The same BP value may call for a beta blocker, arterial vasodilator, nitrate, or alpha blocker depending on the injured organ and the pathophysiology driving the emergency (Williams et al., 2026).
Agent | Typical starting dose | Clinical fit / caution |
|---|---|---|
Nicardipine | 5 mg/h; increase by 2.5 mg/h every 5-15 min; max 15 mg/h | Versatile titratable arterial vasodilator; widely used in neurologic emergencies; avoid as sole strategy for aortic dissection |
Clevidipine | 1–2 mg/h initially; rapid titration. Most patients require ≤16 mg/h; short-term experience at 32 mg/h is limited. (Chiesi USA, Inc., 2025) | Lipid emulsion: contraindicated with soy/egg allergy, defective lipid metabolism, or severe aortic stenosis. Observe 24-h lipid-load limit (≤1,000 mL or average 21 mg/h over 24 h per label). |
Labetalol | IV bolus: 20 mg initially, then 40–80 mg every 10 min (total up to 300 mg); or infusion about 2 mg/min (Hikma Pharmaceuticals USA Inc., 2025) | Adjust to clinical indication and BP response; avoid with severe bradycardia, high-grade heart block, cardiogenic shock, or acute decompensated HF. |
Esmolol | Common initial regimen: 500 mcg/kg IV over 1 min, then 50 mcg/kg/min with titration. A separate 1 mg/kg over 30 sec loading option is labeled for immediate perioperative control; not interchangeable. (Mylan Institutional LLC, 2025) | Short-acting beta1 blocker for rapid heart-rate/shear control in selected aortic emergencies. Assess bradycardia, heart block, acute decompensated HF, cardiogenic shock, and interactions with IV cardiodepressant CCBs. |
Nitroglycerin | 5 mcg/min IV initially with nonadsorptive tubing; increase by 5 mcg/min every 3–5 min initially (American Regent, Inc., 2021) | Titrate to BP and ischemic symptoms. Avoid recent PDE5 inhibitor use and account for infusion-set drug adsorption. |
Nitroprusside | 0.3 mcg/kg/min initially; titrate carefully (maximum 10 mcg/kg/min) (Somerset Therapeutics, LLC, 2025) | Continuous BP monitoring; risk of cyanide/thiocyanate toxicity increases with dose, duration, and renal/hepatic impairment. At 10 mcg/kg/min, do not continue more than 10 minutes; discontinue if BP remains uncontrolled. The maximum is not a routine therapeutic target. |
Hydralazine | 10 mg IV in selected protocols; reassess before repeating. U.S. label lists 20–40 mg IV/IM as the usual dose when oral therapy is unavailable; lower doses may be warranted (DailyMed, n.d.-c). | Variable, delayed peak BP effect (typically 10–80 min); monitor closely for overshoot hypotension and reflex tachycardia. Pregnancy-specific treatment follows obstetric protocols, which may use lower IV doses. The selected U.S. label lists coronary artery disease and rheumatic mitral valvular disease as contraindications; protocol-specific lower doses must not be presented as FDA standard dosing (Meitheal Pharmaceuticals Inc., 2026). |
Phentolamine | 5 mg IV for adult pheochromocytoma-associated perioperative hypertensive episodes; repeat dosing is response- and protocol-dependent. | Alpha blockade for catecholamine-mediated hypertension. The FDA label supports 5 mg IV perioperatively in pheochromocytoma; other crisis applications and repeat intervals require syndrome-specific guidance. |
Aortic Dissection: Reduce Shear Before Vasodilating
Acute aortic dissection is an exception to gradual BP lowering. Begin IV beta blockade (commonly esmolol or labetalol) to reduce heart rate and shear stress, then add a titratable vasodilator only if needed after rate control. The 2025 hypertension guideline recommends SBP ≤120 mm Hg within approximately 20 minutes, provided organ perfusion is maintained. Starting with a vasodilator before rate control can cause reflex tachycardia (Williams et al., 2026; Jones et al., 2025).
Acute Pulmonary Edema or ACS
For hypertensive acute pulmonary edema, IV nitroglycerin, clevidipine, or nitroprusside can reduce congestion and afterload; avoid initiating beta blockers during acute pulmonary edema. With concurrent ACS, IV nitroglycerin can also relieve ischemia, but drug selection depends on perfusion and other contraindications. Beta blockers may have a role in stable ACS yet should not be reflexively initiated in decompensated pulmonary edema or cardiogenic shock (Williams et al., 2026; Jones et al., 2025).
Acute Ischemic Stroke Uses Reperfusion-Specific Targets
Do not apply the generic 25%-in-the-first-hour rule to every stroke. For patients eligible for IV thrombolysis, lower BP to ≤185/110 mm Hg before treatment and maintain ≤180/105 mm Hg for the first 24 hours afterward; endovascular-thrombectomy pathways require additional procedure-specific BP considerations. Without reperfusion, BP is often left untreated unless it exceeds approximately 220/120 mm Hg or another end-organ indication requires treatment. If treatment is necessary, a reduction of about 15% over the first 24 hours is generally used (Prabhakaran et al., 2026; Winkler, 2026).
Pregnancy and Catecholamine Excess
In pregnancy, persistent SBP ≥160 mm Hg or DBP ≥110 mm Hg, confirmed within 15 minutes, warrants prompt treatment to below 160/110 mm Hg within 30–60 minutes. IV labetalol, IV hydralazine, and immediate-release oral nifedipine are first-line acute options, selected according to contraindications. Immediate-release nifedipine is used for acute treatment; extended-release nifedipine is used for maintenance. ACE inhibitors, ARBs, and direct renin inhibitors should be avoided in pregnancy (Jones et al., 2025). Pheochromocytoma-related crisis requires prompt specialist-directed alpha blockade, such as IV phentolamine. If beta blockade is needed for tachycardia, it follows adequate alpha blockade. Stimulant-associated hypertension has a different management context and should not automatically be treated using a pheochromocytoma protocol (Lenders et al., 2014).
Monitoring and Transition to Oral Therapy
- Continuous BP monitoring and frequent neurologic/cardiopulmonary reassessment during active titration.
- Kidney function, urine output, ECG, troponin, electrolytes, and imaging according to the injured organ.
- Watch for overshoot hypotension, AKI, myocardial ischemia, and neurologic worsening from excessive BP reduction.
- Once the emergency is controlled and the patient is stable, transition deliberately to an oral regimen that addresses the chronic cause of hypertension and improves adherence.
- Investigate precipitating factors: medication nonadherence, withdrawal, NSAIDs/stimulants, renal disease, endocrine causes, pregnancy, pain, or acute vascular disease.
High-Yield Distinctions
- Hypertensive emergency = severe BP elevation plus acute target-organ injury.
- For most emergencies, reduce BP in a controlled stepwise fashion rather than normalizing it immediately.
- Aortic dissection requires rapid beta blockade and a lower SBP target than the general emergency algorithm.
- Nitroglycerin is especially useful when severe hypertension coexists with ACS or acute pulmonary edema.
- Stroke has its own BP thresholds; reperfusion eligibility changes the treatment target.
- Severe asymptomatic hypertension usually does not justify IV emergency therapy.
Related YourDNP Resources
- Hypertension Pharmacotherapy
- Stroke & TIA Pharmacotherapy
- Acute Coronary Syndromes Pharmacotherapy
- Heart Failure Pharmacotherapy
- Acute Kidney Injury
Content last reviewed:
References
American Regent, Inc. (2021). Nitroglycerin injection, USP [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c52cdf6-87be-4719-b105-f08be096d462
Chiesi USA, Inc. (2025). Cleviprex (clevidipine) injectable emulsion [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9290625-b723-4eda-bab8-a97bef6041f6
Hikma Pharmaceuticals USA Inc. (2025). Labetalol hydrochloride injection [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99a715a0-4579-410c-b102-7ef6fab8db55
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., Carter, J., Cohen, J. B., Collins, K. J., Commodore-Mensah, Y., Davis, L. L., Egan, B., Khan, S. S., Lloyd-Jones, D. M., Melnyk, B. M., . . . Williamson, J. D. (2025). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 152(11), e114–e218. https://doi.org/10.1161/CIR.0000000000001356
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F., Jr. (2014). Pheochromocytoma and paraganglioma: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 99(6), 1915–1942. https://doi.org/10.1210/jc.2014-1498
Meitheal Pharmaceuticals Inc. (2026). Hydralazine hydrochloride injection, USP [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3c806a4-b971-421c-bcb9-9979c6d7aaec
Mylan Institutional LLC. (2025). Esmolol hydrochloride injection [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f069f9-dd52-4a69-a103-ebdb4294f088
Prabhakaran, S., Gonzalez, N. R., Zachrison, K. S., Adeoye, O., Alexandrov, A. W., Ansari, S. A., Chapman, S., Czap, A. L., Dumitrascu, O. M., Ishida, K., Jadhav, A. P., Johnson, B., Johnston, K. C., Khatri, P., Kimberly, W. T., Lee, V. H., Leslie-Mazwi, T. M., Mac Grory, B., Madsen, T. E., . . . Yaghi, S. (2026). 2026 guideline for the early management of patients with acute ischemic stroke: A guideline from the American Heart Association/American Stroke Association. Stroke, 57(8), e316–e436. https://doi.org/10.1161/STR.0000000000000513
Somerset Therapeutics, LLC. (2025). Sodium nitroprusside injection [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2122b9c1-0af4-493b-82cc-63eee02f987f
Williams, C., Finks, S. W., & Chisholm-Burns, M. A. (2026). Hypertension. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 139-183). McGraw Hill.
Winkler, S. R. (2026). Stroke. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 448-477). McGraw Hill.